- Home
- GMAB vs GGG Comparison
GMAB vs GGG Comparison
Compare GMAB & GGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- GGG
- Stock Information
- Founded
- GMAB 1999
- GGG 1926
- Country
- GMAB Denmark
- GGG United States
- Employees
- GMAB N/A
- GGG N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- GGG Fluid Controls
- Sector
- GMAB Health Care
- GGG Industrials
- Exchange
- GMAB Nasdaq
- GGG Nasdaq
- Market Cap
- GMAB 13.7B
- GGG 14.0B
- IPO Year
- GMAB N/A
- GGG N/A
- Fundamental
- Price
- GMAB $20.62
- GGG $85.81
- Analyst Decision
- GMAB Buy
- GGG Hold
- Analyst Count
- GMAB 9
- GGG 3
- Target Price
- GMAB $39.17
- GGG $87.00
- AVG Volume (30 Days)
- GMAB 1.5M
- GGG 709.4K
- Earning Date
- GMAB 08-07-2025
- GGG 07-23-2025
- Dividend Yield
- GMAB N/A
- GGG 1.28%
- EPS Growth
- GMAB 276.80
- GGG N/A
- EPS
- GMAB 18.36
- GGG 2.83
- Revenue
- GMAB $3,230,902,140.00
- GGG $2,149,411,000.00
- Revenue This Year
- GMAB $747.74
- GGG $7.56
- Revenue Next Year
- GMAB $14.81
- GGG $4.05
- P/E Ratio
- GMAB $1.12
- GGG $30.44
- Revenue Growth
- GMAB 25.43
- GGG N/A
- 52 Week Low
- GMAB $17.24
- GGG $72.06
- 52 Week High
- GMAB $28.56
- GGG $92.86
- Technical
- Relative Strength Index (RSI)
- GMAB 40.36
- GGG 57.90
- Support Level
- GMAB $20.31
- GGG $83.50
- Resistance Level
- GMAB $20.74
- GGG $85.06
- Average True Range (ATR)
- GMAB 0.34
- GGG 1.19
- MACD
- GMAB -0.28
- GGG 0.06
- Stochastic Oscillator
- GMAB 3.90
- GGG 96.14
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About GGG Graco Inc.
Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.